California’s Latest Psychedelics Bill Dies in Committee
Reading Time: 2 minutes Despite efforts by the bill’s authors and advocates to play to the tune of state
Reading Time: 2 minutes Despite efforts by the bill’s authors and advocates to play to the tune of state
Reading Time: 2 minutes Featured content in this Issue: Tempering Excitement Around Recent Raises Compass Shares Cut of Open-Label
Reading Time: < 1 minute AbbVie has become the latest large pharmaceutical company to dip its toes into neuroplastogen research
Reading Time: < 1 minute On Tuesday, Dr. Steffen Thirstrup, Chief Medical Officer (CMO) of the European Medicines Agency (EMA),
Reading Time: < 1 minute Reunion Neuroscience, a New Jersey biotech that spun out from the ill-fated ketamine clinic chain Field
Reading Time: < 1 minute General Overview First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium
Reading Time: < 1 minute Featured content in this Issue: EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as
Reading Time: < 1 minute On Tuesday the 16th and Wednesday the 17th of April, the European Medicines Agency (EMA)
Reading Time: < 1 minute Featured content in this Issue: Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure”
Reading Time: < 1 minute Psychedelic Alpha’s Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, Vice President Psychiatry Development at Neurocrine Biosciences.